{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:18:22Z","timestamp":1783138702015,"version":"3.54.6"},"reference-count":58,"publisher":"Japan Endocrine Society","issue":"7","funder":[{"DOI":"10.13039\/100015060","name":"Nagasaki University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Program of the Network-Type Joint Usage\/Research Center for Radiation Disaster Medical Science"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej25-0565","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:10:34Z","timestamp":1777414234000},"page":"867-881","source":"Crossref","is-referenced-by-count":0,"title":["A predictive nomogram for progression-free survival in radioiodine-refractory papillary thyroid carcinoma after reoperation: a longitudinal study in Vietnam"],"prefix":"10.1507","volume":"73","author":[{"given":"Nguyen Thi","family":"Nhung","sequence":"first","affiliation":[{"name":"Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Ngoc","family":"Ha","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, 108 Military Central Hospital, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Dong","family":"Hoang","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinical Trial Unit Fiona Stanley Hospital, Murdoch WA 6150, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7315-7725","authenticated-orcid":false,"given":"Zhanna","family":"Mussazhanova","sequence":"additional","affiliation":[{"name":"Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan"},{"name":"Department of Fundamental Medicine, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kurohama","sequence":"additional","affiliation":[{"name":"Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan"},{"name":"Thyroid Cancer Collaborative Research Center, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan"},{"name":"Thyroid Cancer Collaborative Research Center, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan"},{"name":"Thyroid Cancer Collaborative Research Center, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Thi Khanh","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Oncology, Friendship Hospital, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngo Thi Minh","family":"Hanh","sequence":"additional","affiliation":[{"name":"Department of Pathology, 108 Military Central Hospital, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Phu Thang","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan"},{"name":"Department of Pathology, 108 Military Central Hospital, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Ngoc Anh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Ultrasound, 108 Military Central Hospital, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsiaryna","family":"Tratsiakova","sequence":"additional","affiliation":[{"name":"Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Matsuse","sequence":"additional","affiliation":[{"name":"Thyroid Cancer Collaborative Research Center, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan"},{"name":"Department of Molecular Oncology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2744-8046","authenticated-orcid":false,"given":"Norisato","family":"Mitsutake","sequence":"additional","affiliation":[{"name":"Thyroid Cancer Collaborative Research Center, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan"},{"name":"Department of Molecular Oncology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-8735","authenticated-orcid":false,"given":"Masahiro","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan"},{"name":"Thyroid Cancer Collaborative Research Center, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, et al. (2021) Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol 9: 225\u2013234.","DOI":"10.1016\/S2213-8587(21)00027-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Grogan RH, Kaplan SP, Cao H, Weiss RE, Degroot LJ, et al. (2013) A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery 154: 1436\u20131446; discussion 1446\u20131437.","DOI":"10.1016\/j.surg.2013.07.008"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3 Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, et al. (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26: 1\u2013133.","DOI":"10.1089\/thy.2015.0020"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Lee HS, Roh JL, Gong G, Cho KJ, Choi SH, et al. (2015) Risk factors for re-recurrence after first reoperative surgery for locoregional recurrent\/persistent papillary thyroid carcinoma. World J Surg 39: 1943\u20131950.","DOI":"10.1007\/s00268-015-3052-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, et al. (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91: 2892\u20132899.","DOI":"10.1210\/jc.2005-2838"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, et al. (2015) Lenvatinib <i>versus<\/i> placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372: 621\u2013630.","DOI":"10.1056\/NEJMoa1406470"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, et al. (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384: 319\u2013328.","DOI":"10.1016\/S0140-6736(14)60421-9"},{"key":"8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1186\/s12885-024-12546-6","volume":"24","author":"B Zhou","year":"2024","unstructured":"8 Zhou B, Liu J, Yang Y, Ye X, Liu Y, et al. (2024) Ultrasound-based nomogram to predict the recurrence in papillary thyroid carcinoma using machine learning. BMC Cancer 24: 810.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Li Y, Tian J, Jiang K, Wang Z, Gao S, et al. (2023) Risk factors and predictive model for recurrence in papillary thyroid carcinoma: a single-center retrospective cohort study based on 955 cases. Front Endocrinol (Lausanne) 14: 1268282.","DOI":"10.3389\/fendo.2023.1268282"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Park YM, Lee BJ (2021) Machine learning-based prediction model using clinico-pathologic factors for papillary thyroid carcinoma recurrence. Sci Rep 11: 4948.","DOI":"10.1038\/s41598-021-84504-2"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11 Jianyong L, Jinjing Z, Zhihui L, Tao W, Rixiang G, et al. (2018) A nomogram based on the characteristics of metastatic lymph nodes to predict papillary thyroid carcinoma recurrence. Thyroid 28: 301\u2013310.","DOI":"10.1089\/thy.2017.0422"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Tan G, Jin B, Qian X, Wang Y, Zhang G, et al. (2024) TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer. Sci Rep 14: 23719.","DOI":"10.1038\/s41598-024-75087-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Steinberg E, Dimitstein O, Morand GB, Forest VI, da Silva SD, et al. (2024) Clinical and histopathological features of thyroid cancer with TERT promoter molecular alterations in isolation <i>versus<\/i> with concurrent molecular alterations: a multicenter retrospective study. Cancers (Basel) 16: 3446.","DOI":"10.3390\/cancers16203446"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Chen B, Shi Y, Xu Y, Zhang J (2021) The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 94: 731\u2013742.","DOI":"10.1111\/cen.14316"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Sun W, Di L, Chen L, Li D, Wu Y, et al. (2022) The outcomes and prognostic factors of patients who underwent reoperation for persistent\/recurrent papillary thyroid carcinoma. BMC Surg 22: 374.","DOI":"10.1186\/s12893-022-01819-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Xu S, Li Q, Wang Z, Huang H, Wang X, et al. (2021) Evaluating the risk of re-recurrence in patients with persistent\/recurrent thyroid carcinoma after initial reoperation. Surgery 169: 837\u2013843.","DOI":"10.1016\/j.surg.2020.09.033"},{"key":"17","unstructured":"17 Lamartina L, Borget I, Mirghani H, Al Ghuzlan A, Berdelou A, et al. (2017) Surgery for neck recurrence of differentiated thyroid cancer: outcomes and risk factors. J Clin Endocrinol Metab 102: 1020\u20131031."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Jeong SI, Kim W, Yu HW, Choi JY, Ahn CH, et al. (2023) Incidence and clinicopathological features of differentiated high-grade thyroid carcinomas: an institutional experience. Endocr Pathol 34: 287\u2013297.","DOI":"10.1007\/s12022-023-09778-w"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Matsuse M, Yabuta T, Saenko V, Hirokawa M, Nishihara E, et al. (2017) TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors. Sci Rep 7: 41752.","DOI":"10.1038\/srep41752"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Ito Y, Miyauchi A, Kakudo K, Hirokawa M, Kobayashi K, et al. (2010) Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma. World J Surg 34: 3015\u20133021.","DOI":"10.1007\/s00268-010-0746-3"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Coca-Pelaz A, Rodrigo JP, Shah JP, Nixon IJ, Hartl DM, et al. (2023) Recurrent differentiated thyroid cancer: the current treatment options. Cancers (Basel) 15: 2692.","DOI":"10.3390\/cancers15102692"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418\u2013428.","DOI":"10.1016\/0002-9343(94)90321-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Nhung NT, Hoang VD, Mussazhanova Z, Kurohama H, Ha LN, et al. (2025) BRAF V600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression. Endocr Connect 14: e250116.","DOI":"10.1530\/EC-25-0116"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24 Ringel MD, Sosa JA, Baloch Z, Bischoff L, Bloom G, et al. (2025) 2025 American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer. Thyroid 35: 841\u2013985.","DOI":"10.1177\/10507256251363120"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Bartel TB, Magerefteh S, Avram AM, Balon HR, De Blanche LE, et al. (2020) SNMMI procedure standard for scintigraphy for differentiated thyroid cancer. J Nucl Med Technol 48: 202\u2013209.","DOI":"10.2967\/jnmt.120.243626"},{"key":"26","unstructured":"26 Avram AM, Giovanella L, Greenspan B, Lawson SA, Luster M, et al. (2022) SNMMI Procedure Standard\/EANM Practice Guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version. J Nucl Med 63: 15N\u201335N."},{"key":"27","doi-asserted-by":"publisher","unstructured":"27 Tuttle RM, Haugen B, Perrier ND (2017) Updated American Joint Committee on Cancer\/Tumor-Node-Metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid 27: 751\u2013756.","DOI":"10.1089\/thy.2017.0102"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Roh JL, Park JW, Jeong J, Gong G, Cho KJ, et al. (2017) Extranodal extension of lymph node metastasis as a prognostic indicator of recurrence and survival in papillary thyroid carcinoma. J Surg Oncol 116: 450\u2013458.","DOI":"10.1002\/jso.24713"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Genpeng L, Pan Z, Tao W, Rixiang G, Jingqiang Z, et al. (2022) Prognostic implications of extranodal extension in papillary thyroid carcinomas: a propensity score matching analysis and proposal for incorporation into current tumor, lymph node, metastasis staging. Surgery 171: 368\u2013376.","DOI":"10.1016\/j.surg.2021.07.018"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, et al. (2022) Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 33: 27\u201363.","DOI":"10.1007\/s12022-022-09707-3"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Bongers PJ, Kluijfhout WP, Verzijl R, Lustgarten M, Vermeer M, et al. (2019) Papillary thyroid cancers with focal tall cell change are as aggressive as tall cell variants and should not be considered as low-risk disease. Ann Surg Oncol 26: 2533\u20132539.","DOI":"10.1245\/s10434-019-07444-2"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Vuong HG, Long NP, Anh NH, Nghi TD, Hieu MV, et al. (2018) Papillary thyroid carcinoma with tall cell features is as aggressive as tall cell variant: a meta-analysis. Endocr Connect 7: R286\u2013R293.","DOI":"10.1530\/EC-18-0333"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Liu Z, Kakudo K, Bai Y, Li Y, Ozaki T, et al. (2011) Loss of cellular polarity\/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition. J Clin Pathol 64: 325\u2013329.","DOI":"10.1136\/jcp.2010.083956"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Kakudo K, Tang W, Ito Y, Mori I, Nakamura Y, et al. (2004) Papillary carcinoma of the thyroid in Japan: subclassification of common type and identification of low risk group. J Clin Pathol 57: 1041\u20131046.","DOI":"10.1136\/jcp.2004.017889"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Donaldson LB, Yan F, Morgan PF, Kaczmar JM, Fernandes JK, et al. (2021) Hobnail variant of papillary thyroid carcinoma: a systematic review and meta-analysis. Endocrine 72: 27\u201339.","DOI":"10.1007\/s12020-020-02505-z"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Asioli S, Erickson LA, Righi A, Lloyd RV (2013) Papillary thyroid carcinoma with hobnail features: histopathologic criteria to predict aggressive behavior. Hum Pathol 44: 320\u2013328.","DOI":"10.1016\/j.humpath.2012.06.003"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Sauerbrei W, Royston P, Binder H (2007) Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 26: 5512\u20135528.","DOI":"10.1002\/sim.3148"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Hirokawa M, Matsuda K, Kudo T, Higuchi M, Suzuki A, et al. (2019) Cribriform-morular variant of papillary thyroid carcinoma shows high Ki-67 labeling indices, despite its excellent prognosis. Pathobiology 86: 248\u2013253.","DOI":"10.1159\/000501097"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Miyauchi A, Kudo T, Hirokawa M, Ito Y, Kihara M, et al. (2013) Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma. Eur Thyroid J 2: 57\u201364.","DOI":"10.1159\/000347148"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Nakao T, Matsuse M, Saenko V, Rogounovitch T, Tanaka A, et al. (2021) Preoperative detection of the TERT promoter mutations in papillary thyroid carcinomas. Clin Endocrinol (Oxf) 95: 790\u2013799.","DOI":"10.1111\/cen.14567"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Tanaka A, Matsuse M, Saenko V, Nakao T, Yamanouchi K, et al. (2019) TERT mRNA Expression as a Novel Prognostic Marker in Papillary Thyroid Carcinomas. Thyroid 29: 1105\u20131114.","DOI":"10.1089\/thy.2018.0695"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228\u2013247.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Cavalheiro BG, Shah JP, Randolph GW, Medina JE, Tufano RP, et al. (2023) Management of recurrent well-differentiated thyroid carcinoma in the neck: a comprehensive review. Cancers (Basel) 15: 923.","DOI":"10.3390\/cancers15030923"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Volinsky CT, Madigan D, Raftery AE, Kronmal RA (1997) Bayesian model averaging in proportional hazard models: assessing the risk of a stroke. J R Stat Soc Ser C Appl Stat 46: 433\u2013448.","DOI":"10.1111\/1467-9876.00082"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Genell A, Nemes S, Steineck G, Dickman PW (2010) Model selection in medical research: a simulation study comparing Bayesian model averaging and stepwise regression. BMC Med Res Methodol 10: 108.","DOI":"10.1186\/1471-2288-10-108"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KG (2003) Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol 56: 441\u2013447.","DOI":"10.1016\/S0895-4356(03)00047-7"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Kim SY, Kim YI, Kim HJ, Chang H, Kim SM, et al. (2021) New approach of prediction of recurrence in thyroid cancer patients using machine learning. Medicine (Baltimore) 100: e27493.","DOI":"10.1097\/MD.0000000000027493"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Liu R, Zhu G, Tan J, Shen X, Xing M (2024) Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness. J Natl Cancer Inst 116: 694\u2013701.","DOI":"10.1093\/jnci\/djad265"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Rashid FA, Munkhdelger J, Fukuoka J, Bychkov A (2020) Prevalence of <i>BRAF<sup>V600E<\/sup><\/i> mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review. Gland Surg 9: 1878\u20131900.","DOI":"10.21037\/gs-20-430"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Toda S, Iwasaki H, Okubo Y, Hayashi H, Kadoya M, et al. (2024) The frequency of mutations in advanced thyroid cancer in Japan: a single-center study. Endocr J 71: 31\u201337.","DOI":"10.1507\/endocrj.EJ23-0342"},{"key":"51","doi-asserted-by":"publisher","unstructured":"51 Meng Z, Matsuse M, Saenko V, Yamashita S, Ren P, et al. (2019) TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower <sup>131<\/sup>i uptake in metastases. IUBMB Life 71: 1030\u20131040.","DOI":"10.1002\/iub.2056"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Mu Z, Zhang X, Liang D, Fang J, Chen G, et al. (2024) Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer. Chin J Cancer Res 36: 25\u201335.","DOI":"10.21147\/j.issn.1000-9604.2024.01.03"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Yang X, Li J, Li X, Liang Z, Gao W, et al. (2017) TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer. J Nucl Med 58: 258\u2013265.","DOI":"10.2967\/jnumed.116.180240"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Vuong HG, Altibi AM, Duong UN, Ngo HT, Pham TQ, et al. (2017) Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis. Tumour Biol 39: 1010428317713913.","DOI":"10.1177\/1010428317713913"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, et al. (2019) 2019 European Thyroid Association Guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J 8: 227\u2013245.","DOI":"10.1159\/000502229"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Hysek M, Jatta K, Hellgren LS, Stenman A, Larsson C, et al. (2021) Spatial distribution patterns of clinically relevant TERT promoter mutations in follicular thyroid tumors of uncertain malignant potential: advantages of the digital droplet PCR technique. J Mol Diagn 23: 212\u2013222.","DOI":"10.1016\/j.jmoldx.2020.10.016"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Wang Z, Sun K, Jing C, Cao H, Ma R, et al. (2019) Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAFV600E mutation in papillary thyroid carcinoma. J Clin Lab Anal 33: e22902.","DOI":"10.1002\/jcla.22902"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Nguyen HT, Nguyen BT, Tran AV, Nguyen TT, Ngo LH, et al. (2025) A predictive nomogram for selective screening of asymptomatic vertebral fractures: the Vietnam Osteoporosis Study. Osteoporos Sarcopenia 11: 9\u201314.","DOI":"10.1016\/j.afos.2024.12.002"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/7\/73_EJ25-0565\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:42:32Z","timestamp":1783136552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/7\/73_EJ25-0565\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0565","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ25-0565"}}